Prasol Chemicals Limited – Investor Presentation Summary
Key Operational Highlights
- Total revenue was ₹433.6 crores, a growth of 36% YoY.
- Growth was driven by steady volume growth, a better product mix, and higher realisations.
- Domestic sales grew strongly in both value and volume, backed by healthy demand for value-added products.
- Exports grew year-on-year, though geopolitical tensions in West Asia held back shipments.
- Product mix improved as secondary and tertiary derivatives grew in both the acetone and phosphorus value chain.
- Mahad facility had its best-ever quarterly production, and capacity utilisation improved.
- The company continues to focus on efficiency, cost reduction, and better yields for selected products.
- Capacity expansion at both Khopoli and Mahad locations is on schedule.
Key drivers of operational performance: Better realisations, higher volumes, improving product mix, and sustainable improvement in utilizations at the Mahad facility.
Financial Highlights
- Revenue: ₹433.6 crores
- EBITDA: ₹90.3 crores
- PAT: ₹61.0 crores
- EPS: ₹10.52
- Margins: Gross Margin 37.9%, EBITDA Margin 20.8%, PAT Margin 14.1%
- YoY comparison: Revenue up 35.5%, EBITDA up 122.4%, PAT up 150.7%
- Drivers of financial performance: Margins were positively impacted by an average selling price increase on account of geopolitical-led supply chain issues (₹25 crores) and foreign currency fluctuations (₹0.92 crores); normalisation is expected in coming quarters.
- Comparison to market estimates: Not Specified
- Key Risks: Geopolitical tensions, supply chain issues, foreign currency fluctuations.
Geographical Revenue Split
- Domestic vs Export Revenue: Not quantitatively specified, but domestic sales grew strongly while exports grew YoY but were held back by West Asia conflict.
- Regional Breakdown: Not Specified
Balance Sheet Snapshot
- Net Debt/Equity: 0.19x (as of FY26)
- Reserves: Not Specified in presentation
- Current Assets/Liabilities: Current Assets ₹474.2 crores, Current Liabilities ₹307.7 crores (as of Mar-26)
- Working Capital/Leverage Metrics: Net Working Capital Days 83.1 (as of FY26)
- Financial Health Insights: Strong cash flow generation, improved liquidity.
Capex & Cash Flow Health
- Capital Expenditure: Phase I Expansion in Existing Products: ₹250-300 crores; Phase II Expansion for New R&D Products: ₹250-300 crores.
- Free Cash Flow: Not Specified
- Operating Cash Flow: Net cash from operating activities was ₹49.5 crores (FY26).
- Net Debt Movement: Not Specified for quarter
- Investment Rationale: Debottlenecking and process augmentation at existing units, land & infrastructure development, venturing into new product lines with higher margins.
Strategic & R&D Initiatives
- Investments in Innovation: Developing more than 40 new products at various stages; several expected to be commercialised in coming years.
- Expected impact on growth: Aspire to achieve ₹2,800 - ₹3,000 crores revenue over next 5 years.
- Strategic Rationale: Expanding capabilities across both existing and new products, diversifying across industries and geographies.
Industry Trends & Business Environment
- Macro/Industry Trends: Rapid urbanization and infrastructure development; geopolitical tensions; supply chain challenges.
- Impact on Company: Geopolitical-led supply chain issues positively impacted realizations by ₹25 crores in Q1; West Asia conflict held back export shipments.
Management Commentary & Growth Outlook
- Strategic Outlook: \"We are on a journey of sustained profitability for Prasol.\"
- FY Guidance: FY27 revenue guidance of ₹1,550–1,650 crores; EBITDA guidance of ₹240-250 crores (excluding price fluctuations due to geopolitical-led supply chain issues and forex gains/losses).
- Market Share Targets: Not Specified
- Risks and Opportunities: Geopolitical-led supply chain issues, forex fluctuations, demand environment.
Utilization of IPO Proceeds
- Repayment or prepayment of borrowings: ₹60.0 crores (fully deployed)
- General corporate purposes: ₹16.4 crores (fully deployed)